Literature DB >> 26868528

Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.

Dongye Zhang1, Minyi Hu1, Timothy Chu1, Liangjun Lin1, Jingyu Wang1, Xiaodong Li2, Hua Zhu Ke3, Yi-Xian Qin4.   

Abstract

Osteoporosis is characterized by low bone mass and compromised trabecular architecture, and is commonly occurred in post-menopausal women with estrogen deficiency. In addition, prolonged mechanical unloading, i.e., long term bed rest, can exaggerate the bone loss. Sclerostin is a Wnt signaling antagonist and acts as a negative regulator for bone formation. A sclerostin-neutralizing antibody (Scl-Ab) increased bone mineral density in women with postmenopausal osteoporosis and healthy men. The objective of this study was to characterize the condition of bone loss in ovariectomized (OVX) rats with concurrent mechanical unloading and evaluate the effect of sclerostin antibody treatment in mitigating the prospective severe bone loss conditions in this model. Four-month-old OVX- or sham-operated female SD rats were used in this study. They were subjected to functional disuse induced by hind-limb suspension (HLS) or free ambulance after 2days of arrival. Subcutaneous injections with either vehicle or Scl-Ab at 25mg/kg were made twice per week for 5weeks from the time of HLS. μCT analyses demonstrated a significant decrease in distal metaphyseal trabecular architecture integrity with HLS, OVX and HLS+OVX (bone volume fraction decreased by 29%, 71% and 87% respectively). The significant improvements of various trabecular bone parameters (bone volume fraction increased by 111%, 229% and 297% respectively as compared with placebo group) with the administration of Scl-Ab are associated with stronger mechanical property and increased bone formation by histomorphometry. These results together indicate that Scl-Ab prevented the loss of trabecular bone mass and cortical bone strength in OVX rat model with concurrent mechanical unloading. The data suggested that monoclonal sclerostin-neutralizing antibody represents a promising therapeutic approach for severe osteoporosis induced by estrogen deficiency with concurrent mechanical unloading.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histomorphometry; Mechanical unloading; Post-menopause; Sclerostin antibody; Severe osteoporosis

Mesh:

Substances:

Year:  2016        PMID: 26868528      PMCID: PMC4862887          DOI: 10.1016/j.bone.2016.02.005

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  55 in total

1.  Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody.

Authors:  Mohammad Shahnazari; Thomas Wronski; Vivian Chu; Alyssa Williams; Alicia Leeper; Marina Stolina; Hua Zhu Ke; Bernard Halloran
Journal:  Calcif Tissue Int       Date:  2012-05-27       Impact factor: 4.333

2.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

Review 3.  Mechanisms of bone remodeling during weight-bearing exercise.

Authors:  Ronald Zernicke; Christopher MacKay; Caeley Lorincz
Journal:  Appl Physiol Nutr Metab       Date:  2006-12       Impact factor: 2.665

4.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

Review 5.  Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

Authors:  Maurizio Rossini; Davide Gatti; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

6.  Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium.

Authors:  S L Alatalo; J M Halleen; T A Hentunen; J Mönkkönen; H K Väänänen
Journal:  Clin Chem       Date:  2000-11       Impact factor: 8.327

7.  Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Authors:  Faryal S Mirza; I Desmond Padhi; Lawrence G Raisz; Joseph A Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

8.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

9.  Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading.

Authors:  Jordan M Spatz; Rachel Ellman; Alison M Cloutier; Leeann Louis; Miranda van Vliet; Larry J Suva; Denise Dwyer; Marina Stolina; Hua Zhu Ke; Mary L Bouxsein
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

10.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

View more
  7 in total

Review 1.  Osteocytes and Estrogen Deficiency.

Authors:  Laoise M McNamara
Journal:  Curr Osteoporos Rep       Date:  2021-11-26       Impact factor: 5.096

Review 2.  Drug discovery of sclerostin inhibitors.

Authors:  Sifan Yu; Dijie Li; Ning Zhang; Shuaijian Ni; Meiheng Sun; Luyao Wang; Huan Xiao; Dingdong Liu; Jin Liu; Yuanyuan Yu; Zongkang Zhang; Samuel Tin Yui Yeung; Shu Zhang; Aiping Lu; Zhenlin Zhang; Baoting Zhang; Ge Zhang
Journal:  Acta Pharm Sin B       Date:  2022-01-21       Impact factor: 14.903

3.  Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury.

Authors:  Ean G Phillips; Luke A Beggs; Fan Ye; Christine F Conover; Darren T Beck; Dana M Otzel; Payal Ghosh; Anna C F Bassit; Stephen E Borst; Joshua F Yarrow
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

4.  Soy protein improves tibial whole-bone and tissue-level biomechanical properties in ovariectomized and ovary-intact, low-fit female rats.

Authors:  Pamela S Hinton; Laura C Ortinau; Rebecca K Dirkes; Emily L Shaw; Matthew W Richard; Terese Z Zidon; Steven L Britton; Lauren G Koch; Victoria J Vieira-Potter
Journal:  Bone Rep       Date:  2018-05-18

5.  Sustained-release of sclerostin single-chain antibody fragments using poly(lactic-co-glycolic acid) microspheres for osteoporotic fracture repair.

Authors:  Ming Li; Shifei Li; Jianheng Liu; Xiang Cui; Shudong Zhang; Jian Zhou; Xiumei Wang; Qi Yao
Journal:  J Biomed Mater Res A       Date:  2019-05-10       Impact factor: 4.396

6.  Cell-Free Fat Extract Prevents Tail Suspension-Induced Bone Loss by Inhibiting Osteocyte Apoptosis.

Authors:  Mingming Xu; Jingke Du; Junqi Cui; Shuangyan Zhang; Shuhong Zhang; Mingwu Deng; Wenjie Zhang; Hanjun Li; Zhifeng Yu
Journal:  Front Bioeng Biotechnol       Date:  2022-01-28

7.  Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.

Authors:  H Allison; G Holdsworth; L M McNamara
Journal:  BMC Mol Cell Biol       Date:  2020-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.